Fresenius Medical upgraded to Buy from Hold at Jefferies. Jefferies analyst James Vane-Tempest upgraded Fresenius Medical Care to Buy from Hold with a $44.50 price target. The company's homecare strategy is being underestimated by the market and the roll out of NxStage dialysis products could drive shareholder value, Vane-Tempest tells investors in a research note. The analyst believes Fresenius Medical is among the stocks in European Healthcare that could double over the next five years. source thefly
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.